Kim Jung Han, Kim Bum Jun, Kim Hyeong Su
Division of Hemato-Oncology, Department of Internal Medicine, Kangnam Sacred-Heart Hospital, Hallym University Medical Center, Hallym University College of Medicine, Seoul 07441, Republic of Korea.
Department of Internal Medicine, National Army Capital Hospital, The Armed Forces Medical Command, Sungnam 13574, Republic of Korea.
Oncotarget. 2017 Sep 8;8(43):75478-75487. doi: 10.18632/oncotarget.20796. eCollection 2017 Sep 26.
c-Met overexpression has been observed in renal cell carcinoma (RCC). However, its clinicopathological impacts remain uncertain. We performed this meta-analysis to evaluate the pathologic and prognostic impacts of high c-Met expression in patients with RCC. A systematic computerized search of the electronic databases PubMed and Embase was performed. From 12 studies, 1,724 patients with RCC were included in the meta-analysis. Compared with RCCs showing low c-Met expression, tumors with high c-Met expression showed significantly higher nuclear grade (odds ratio = 2.45 [95% CI: 1.43-4.19], = 0.001) and pT stage (odds ratio = 2.18 [95% CI: 1.27-3.72], = 0.005). In addition, patients with c-Met-high RCC showed significantly worse overall survival than those with c-Met-low tumor (hazard ratio = 1.32 [95% CI: 1.12-1.56], = 0.0009). In conclusion, this meta-analysis demonstrates that high c-Met expression correlate with significantly worse pathological features and overall survival, indicating c-Met overexpression is a potential adverse prognostic marker for patients with RCC.
在肾细胞癌（RCC）中已观察到c-Met过表达。然而，其临床病理影响仍不确定。我们进行了这项荟萃分析，以评估c-Met高表达对RCC患者的病理和预后影响。对电子数据库PubMed和Embase进行了系统的计算机检索。从12项研究中，1724例RCC患者被纳入荟萃分析。与c-Met低表达的RCC相比，c-Met高表达的肿瘤显示出显著更高的核分级（优势比=2.45[95%CI：1.43-4.19]，P=0.001）和pT分期（优势比=2.18[95%CI：1.27-3.72]，P=0.005）。此外，c-Met高表达的RCC患者的总生存期明显比c-Met低表达的肿瘤患者差（风险比=1.32[95%CI：1.12-1.56]，P=0.0009）。总之，这项荟萃分析表明，c-Met高表达与明显更差的病理特征和总生存期相关，表明c-Met过表达是RCC患者潜在的不良预后标志物。
